Constitutively active FOXO4 can reduce tumor onset, size, and progression in nude mice transplanted with Her2-positive breast cancer cells by inhibiting AKT activity, regulating P27 kip1 stability and suppressing HER2-mediated tumorigenicity [119]. This evidence concerns the gene ERBB2 and breast carcinoma.